Hologic, Inc. Files Form S-3 Registration Statement

Hologic, Inc. (NASDAQ: HOLX) today announced that it has filed a Shelf Registration Statement on Form S-3 with the Securities and Exchange Commission covering an offering by it of up to 3,000,000 shares of its common stock. Included in the shelf registration statement is a prospectus for a public offering of 2,000,000 shares of common stock, plus 300,000 shares to cover over-allotments. The Company's financial advisor, Needham & Company, Inc., is the underwriter of the proposed offering. Hologic plans to use the net proceeds of the offering to fund the continued development of its DirectRay® direct-to digital mammography system, including conducting clinical trials and working toward regulatory approvals, as well as to fund research and development and for general corporate purposes and working capital.

Hologic is dedicated to developing and delivering proprietary X-ray and ultrasound systems that incorporate direct-to-digital radiographic imaging technology for both women's health and general radiographic applications. Hologic's business divisions include: the Hologic Radiographic Systems division encompassing general and digital radiography systems; Direct Radiography Corp., a wholly owned subsidiary and manufacturer of state-of-the- art proprietary flat panel technology called DirectRay®; the Hologic Osteoporosis Assessment division; the Lorad® division, specializing in state-of-the-art breast imaging and minimally invasive breast biopsy systems; and Fluoroscan Imaging, a wholly owned subsidiary, manufacturing and marketing state-of-the-art, low intensity, real time X-ray imaging devices.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state where such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state. A Shelf Registration Statement relating to the shares that Hologic intends to sell has been filed with the Securities and Exchange Commission, but has not yet been declared effective. Any offer, if at all, will be made only by means of a prospectus, including a prospectus supplement, forming a part of an effective registration statement.

A copy of the prospectus relating to the offering, when available, may be obtained from Needham & Company at 445 Park Avenue, New York, NY 10022.


SOURCE: Hologic, Inc.

Contact: Glenn P. Muir, Executive Vice President & CFO, +1-781-999-7300, or Marianne Ritchie, Manager, Investor Relations, +1-781-999-7300, both of Hologic, Inc.

Web site: